Metabolic disease and cardiovascular risk in people treated with antipsychotics in the community

Br J Psychiatry. 2007 Jul:191:23-9. doi: 10.1192/bjp.bp.106.031716.

Abstract

Background: Prevalence of physical comorbidity in severe mental illness is a significant public health concern, but comparative data in people with diagnoses other than schizophrenia are sparse.

Aims: To investigate the prevalence of metabolic disease and cardiovascular risk in people with severe mental illness treated with antipsychotics in the community.

Methods: Case-control study of 90 people treated with antipsychotics in the community and 92 age- and gender-matched controls. The prevalence of metabolic syndrome and 10-year cardiovascular risk were calculated.

Results: People on antipsychotics had a significantly worse metabolic profile than controls (F=6.583, d.f.=15,161, P<0.0001). Moreover, metabolic syndrome was more prevalent (OR=3.68, 95% CI 1.71-7.93, P=0.001), as was cardiovascular risk across a number of outcomes. These results are consistent across diagnostic groups.

Conclusions: People with severe mental illness treated with antipsychotics have excess metabolic dysfunction and heightened risk for cardiovascular disease.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Analysis of Variance
  • Antipsychotic Agents / therapeutic use*
  • Cardiovascular Diseases / epidemiology*
  • Case-Control Studies
  • Community Health Services*
  • Comorbidity
  • Female
  • Humans
  • Male
  • Metabolic Diseases / epidemiology*
  • Middle Aged
  • Prevalence
  • Psychotic Disorders / drug therapy
  • Psychotic Disorders / epidemiology*
  • Risk
  • Smoking / adverse effects
  • United Kingdom / epidemiology

Substances

  • Antipsychotic Agents